---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-346888"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2026-08-12T20:15:36+00:00"
generated_at: "2026-08-12T20:17:18.394801+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Atea reports Q2 net loss $32.9M; HCV Phase 3 C-BEYOND hits primary endpoint

## Summary
- Net loss $32.9M ($0.41/sh) vs $37.2M ($0.44/sh) in Q2 2025; cash & investments $219.5M, down from $301.8M at year-end 2025.
- C-BEYOND met primary non-inferiority endpoint: BEM/RZR SVR 93.9% vs SOF/VEL 94.8% in mITT (n=905); SVR 93.5% in non-cirrhotics with 8-week regimen.
- C-FORWARD enrollment completed (880+ patients, 17 countries); topline expected early Q1 2027; NDA submission anticipated Q2 2027.
- AT-587 Phase 1 trial initiated in July 2026 for hepatitis E virus; no approved HEV therapy exists.
- R&D expenses $28.2M in Q2 2026, down from $32.3M year-over-year.

## SEC filing metadata
- accession: 0001193125-26-346888
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2026-08-12T20:15:36+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312526346888/0001193125-26-346888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312526346888/d165663d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-346888
- JSON: https://secwatch.observer/filing/0001193125-26-346888.json
- Plain text: https://secwatch.observer/filing/0001193125-26-346888.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.